# Synthesis Capital

Synthesis Capital is a Private Equity based in London, United Kingdom.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** London, United Kingdom
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** synthesis.capital
- **LinkedIn:** https://www.linkedin.com/company/synthesiscapital

## Regulatory record

- **CRD number:** 312144
- **Registration status:** Registered
- **Reports private funds:** No
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/312144

## About

Synthesis Capital is a state-registered investment adviser with approximately $7 million in regulatory assets under management. The firm has 2 employee and 1 investment adviser. It operates with a small team.

## Sectors

- FoodTech
- AgriTech & FoodTech
- ClimateTech

## People

- Costa Yiannoulis — Managing Partner & Co-Founder
- Rosie Wardle — Partner & Co-Founder

## Questions

### Does Synthesis Capital invest only in alternative-protein companies?

The firm's mandate covers alternative proteins (plant-based, precision fermentation, and cellular agriculture) as well as the enabling infrastructure — including bioreactors, feedstock engineering, and bioprocess optimization — that determines whether these technologies can scale to cost parity. It does not invest in conventional agriculture, food distribution, or restaurant tech.

### How does Synthesis Capital source proprietary deal flow?

The founding team's decade-plus tenure in food-tech venture, dating to CPT Capital's earliest investments in the sector, gives Synthesis access to scientist-founders and university spinouts before generalist venture firms enter competitive processes. The firm also draws on relationships with sovereign wealth funds and family offices that co-invested alongside CPT Capital in prior fund cycles (per Bloomberg, 2023).

### What is Synthesis Capital's known posture on co-investments alongside external GPs?

Synthesis invests primarily as a lead or co-lead in early-stage and growth rounds, with no publicly disclosed fund-of-funds program. Its debut vehicle accepted commitments from institutional LPs rather than operating a co-investment club for family offices or high-net-worth individuals. The firm has not announced a dedicated co-investment vehicle as of mid-2026.

## Related profiles

- [SYNthesis BioVentures](https://altss.com/profile/synthesis-bioventures)
- [SYN Ventures](https://altss.com/profile/syn-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/synthesis-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology